Tourmaline Bio, Inc.
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
TRML | US
Overview
Corporate Details
- ISIN(s):
- US87410C1045 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 27 WEST 24TH STREET, 10010 NEW YORK
- Website:
- https://www.tourmalinebio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company dedicated to developing transformative medicines for patients with life-altering inflammatory and immune diseases. The company's primary focus is its lead candidate, pacibekitug, an anti-IL-6 monoclonal antibody (mAb) being developed as a potential treatment for conditions such as atherosclerotic cardiovascular disease (ASCVD). Tourmaline Bio aims to establish new standards of care in areas with significant unmet medical needs. In a key milestone, the company was acquired by Novartis to complement its cardiovascular drug development pipeline.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Tourmaline Bio, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Tourmaline Bio, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Tourmaline Bio, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
